Jane Street Group LLC acquired a new position in shares of Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 45,549 shares of the company's stock, valued at approximately $749,000. Jane Street Group LLC owned approximately 0.08% of Upstream Bio as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in UPB. US Bancorp DE bought a new stake in Upstream Bio in the 4th quarter valued at approximately $27,000. Legal & General Group Plc acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $28,000. Summit Investment Advisors Inc. acquired a new stake in shares of Upstream Bio in the fourth quarter valued at approximately $30,000. Tower Research Capital LLC TRC bought a new stake in shares of Upstream Bio in the fourth quarter worth $47,000. Finally, Corebridge Financial Inc. acquired a new position in Upstream Bio during the fourth quarter worth $142,000.
Upstream Bio Stock Down 3.8%
Upstream Bio stock traded down $0.35 during mid-day trading on Friday, reaching $9.00. The company's stock had a trading volume of 88,701 shares, compared to its average volume of 283,758. Upstream Bio, Inc. has a 12 month low of $5.14 and a 12 month high of $29.46. The business's 50 day simple moving average is $8.15 and its 200 day simple moving average is $11.98.
Upstream Bio (NASDAQ:UPB - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.51) EPS for the quarter, missing analysts' consensus estimates of ($0.49) by ($0.02). The firm had revenue of $0.57 million for the quarter, compared to the consensus estimate of $0.71 million. Research analysts anticipate that Upstream Bio, Inc. will post -4.3 earnings per share for the current fiscal year.
Upstream Bio Company Profile
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Featured Articles
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
